October 29, 2026

Measles

First Evidence of Measles Virus Detected From Exhaled Breath in Humans
Authors studied a 23-year-old unvaccinated woman with laboratory-confirmed measles (throat-swab RT-qPCR positive on day five post symptom onset). From day 10 post symptom onset, longitudinal sampling was performed for six consecutive days with duplicate specimens collected at each timepoint from the throat, face, cutaneous lesions and exhaled breath using a surgical mask fitted with polyvinyl alcohol sampling strips (FMS). Measles virus RNA was consistently detected in exhaled breath captured by FMS and remained >10ˆ4 genome copies per sampling strip despite sampling beginning 10 days after symptom onset. Although RNA detection does not confirm infectious virus, persistent high-level exhaled RNA supports FMS as a practical, non-invasive tool to study measles respiratory emission and may inform understanding of transmission and the duration of potential contagiousness.

Influenza Vaccination

Effectiveness of High-dose versus Standard-dose Influenza Vaccines against Severe Respiratory and Secondary Cardiovascular Outcomes in Adults Aged ≥80 Years
These are the results of a retrospective, population-based cohort study conducted in Andalusia, Spain, during the 2024–2025 influenza season, including 279,649 vaccinated adults aged ≥80 years. Data on sociodemographic characteristics, influenza vaccines, chronic diseases, and clinical outcomes were taken from the Andalusian health population database. Compared with SD-IIV, HD-IIV was associated with a lower risk of hospitalization for influenza (rVE = 34.0%; 95% CI = 15.8–52.2%). HD-IIV also showed improved effectiveness against laboratory-confirmed influenza (rVE = 42.1%; 95% CI = 22.9–61.3%), hospitalization for acute myocardial infarction (rVE = 26.4%; 95% CI = 5.6–47.2%), for stroke (rVE = 32.9%; 95% CI = 17.4–48.4%), for pulmonary embolism (rVE = 26.7%; 95% CI = 0.7–52.6%) and for overall cardiovascular outcomes (rVE = 6.6%; 95% CI = 0.9–12.2%).

Humoral Immunogenicity of mRNA-1010, an mRNA-Based Seasonal Influenza Vaccine, in Adults ≥50 
Participants were randomized 1:1 to a single dose of mRNA-1010 (37.5-µg) or licensed SD influenza vaccine. Immunogenicity was assessed in a pre-specified per-protocol subset. Anti-hemagglutinin antibody titers were measured by hemagglutination inhibition (HAI) and microneutralization (MN; subset) at baseline and Day 29 against vaccine-matched strains. Outcomes included geometric mean titers (GMTs), geometric mean fold rises (GMFRs) from baseline, and seroconversion rates (SCRs; ≥4-fold rise). In adults ≥50 years, a single dose of mRNA-1010 induced higher humoral immune responses against vaccine-matched influenza strains than licensed SD influenza vaccine. Together with previously reported results, these findings support mRNA-1010 as a seasonal influenza vaccine option in adults ≥50 years.

Situation Dashboards

World_Health_Organization_logo_logotype

World Health Organization (WHO)

Novel Coronavirus (COVID-19) Situation from World Health Organization (WHO)
university-logo-small-horizontal-blue-no-clear-space-51c7fb4524

Johns Hopkins University (JHU)

Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at JHU
1point3acres

COVID-19 in US and Canada

1Point3Acres Real-Time Coronavirus (COVID-19) Updates in US and Canada with Credible Sources
image

Genomic Epidemiology COVID-19

Genomic Epidemiology of (COVID-19) Maintained by the Nextstrain team, enabled by data from GISAID.

Sources for COVID-19 Information

World_Health_Organization_logo_logotype

World Health Organization (WHO)

U.S. Centers for Disease Control and Prevention

Centers for Disease Control, US

International Society for Infectious Diseases

International Society for Infectious Diseases

twiv-logo

This Week in Virology (TWIV)

Row triangle Shape Decorative svg added to bottom

Learn more about parasitic diseases and receive updates about Parasites Without Borders' initiatives and developments by subscribing to our newsletter.

Parasites Without Borders

A comprehensive educational resource on all aspects of parasitic diseases and their impact on humanity around the globe.

Donate to Parasites Without Borders Today!

Help bring the latest medical and basic biological information pertaining to diseases caused by eukaryotic parasites to every practicing physician and medical student within the United States.

Scroll to Top